Medtronic puts Avecor in perfusion division:
This article was originally published in Clinica
Executive Summary
Medtronic has completed its acquisition of Avecor Cardiovascular, which is to be incorporated into Medtronic's reorganised perfusion systems division. The unit includes Medtronic's blood management and cardiopulmonary business. Medtronic says the combined businesses will provide the leading cardiac surgery perfusion product line. Medtronic was forced to increase its bid for Avecor from $11.125 per share to $13 each after the Minneapolis-based company received an offer of $13 from an unnamed third-party (see Clinica No 838, p 10).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.